Irritable Bowel Syndrome Treatment: Market Projected to Reach $2,012 Million by 2026

The market for irritable bowel syndrome (IBS) treatment witnessed significant growth over the past decade, and its upward trajectory is projected to continue in the coming years. In 2018, the global market size for IBS treatment reached a valuation of $1,071 million. However, with the increasing prevalence of IBS and growing awareness about available treatment options, the market is estimated to expand even further, reaching a substantial value of $2,012 million by 2026. This projected growth indicates a robust compound annual growth rate (CAGR) of 8.2% from 2019 to 2026, highlighting the increasing demand for effective therapies for IBS.

The treatment of irritable bowel syndrome typically involves a multifaceted approach aimed at managing symptoms and improving the overall quality of life for affected individuals. Stress relief techniques, such as relaxation exercises, meditation, and counseling, are often recommended as stress can exacerbate IBS symptoms.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:https://www.alliedmarketresearch.com/request-sample/6313

The key players profiled in this report include Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare), Novartis AG, Sebela Pharmaceuticals Inc., and Takeda Pharmaceutical Company Ltd.

The irritable bowel syndrome (IBS) treatment market can be categorized based on several factors, including the type of IBS, the specific products used for treatment, end users, and regions. Here's a breakdown of the market:

By Type of IBS:
IBS with Diarrhea (IBS-D): This type of IBS is characterized by diarrhea as a predominant symptom.
IBS with Constipation (IBS-C): This type of IBS is characterized by constipation as a predominant symptom.
Mixed-presentation IBS (IBS-M): This type of IBS involves a combination of symptoms, including both diarrhea and constipation.
By Product:
Rifaximin: Rifaximin is an antibiotic used to reduce bloating and diarrhea in individuals with IBS-D.
Eluxadoline: Eluxadoline is a medication that helps alleviate abdominal pain and diarrhea in individuals with IBS-D.
Lubiprostone: Lubiprostone is a medication primarily prescribed for IBS-C to relieve constipation by increasing fluid secretion in the intestines.
Linaclotide: Linaclotide is a medication also used for IBS-C, which helps relieve constipation by promoting bowel movements and reducing pain.
Others: This category includes other medications, therapies, or treatment options available for IBS management.
By End User:
Hospitals Pharmacies: These are pharmacies within hospital premises that provide medications for inpatients and outpatients.
Drug Stores & Retail Pharmacies: These are retail outlets where individuals can purchase medications for IBS treatment.
Online Pharmacies: Online platforms where individuals can order medications for IBS treatment and have them delivered to their doorstep.

Purchase Premium Copy of Irritable Bowel Syndrome Treatment Market Growth Report at: https://www.alliedmarketresearch.com/irritable-bowel-syndrome-treatment-market/purchase-options

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

United States
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com

This release was published on openPR.